ABSTRACT
We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in translating ctDNA results into clinical actions. METHODS: In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial manufacturers with variant allele frequencies (VAFs) of 5%, 2.5%, 1%, 0.1%, and 0%. Four laboratories tested samples in quadruplicate using two allele-specific droplet digital polymerase chain reaction and three (amplicon and hybrid capture) next-generation sequencing (NGS) panels. RESULTS: The two droplet digital polymerase chain reaction assays reported VAF values very close to the manufacturers' claimed concentrations for all QCMs. NGS assays reported most single nucleotide variants and indels, but not translocations, close to the expected VAF values. Notably, two NGS assays reported lower VAF than expected for all translocations in all QCM mixtures, possibly related to technical challenges detecting these variants. The ability to call ERBB2 copy number amplifications varied across assays. All three QCMs provided valuable insight into assay precision. Each assay across all variant types demonstrated dropouts at 0.1%, suggesting that the QCM can serve for testing of an assay's limit of detection with confidence claims for specific variants. CONCLUSION: These results support the utility of the QCM in testing ctDNA assay analytical performance. However, unique designs and manufacturing methods for the QCM, and variations in a laboratory's testing configuration, may require testing of multiple QCMs to find the best reagents for accurate result interpretation.
Subject(s)
Circulating Tumor DNA/genetics , High-Throughput Nucleotide Sequencing , Neoplasms/genetics , Polymerase Chain Reaction , Quality Control , Biomarkers, Tumor/genetics , Circulating Tumor DNA/blood , DNA Copy Number Variations , Gene Frequency , Humans , Mutation/genetics , National Institutes of Health (U.S.) , Neoplasms/blood , United StatesABSTRACT
We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were red blood cell (RBC) transfusion dependent at study entry. Dose escalation cohorts examined two once-daily dosing regimens: schedule I (5 days on/9 days off, range of doses studied 1-40 mg, n = 65) and schedule II (21 days on/7 days off, 7-20 mg, n = 19); 27 patients received treatment for ≥180 days. The most common treatment-related, treatment-emergent adverse events included diarrhea, nausea, fatigue, and vomiting. No complete or partial responses meeting IWG criteria were observed; however, RBC transfusion free intervals >56 days were observed in nine patients who were transfusion dependent at study entry (15%). Of 15 MDS patients with missense SF3B1 mutations, five experienced RBC transfusion independence (TI). Elevated pre-treatment expression of aberrant transcripts of Transmembrane Protein 14C (TMEM14C), an SF3B1 splicing target encoding a mitochondrial porphyrin transporter, was observed in MDS patients experiencing RBC TI. In summary, H3B-8800 treatment was associated with mostly low-grade TAEs and induced RBC TI in a biomarker-defined subset of MDS.
Subject(s)
Leukemia, Myeloid, Acute/drug therapy , Myelodysplastic Syndromes/drug therapy , Phosphoproteins/antagonists & inhibitors , Piperazines/therapeutic use , Pyridines/therapeutic use , RNA Splicing Factors/antagonists & inhibitors , Administration, Oral , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Dose-Response Relationship, Drug , Female , Humans , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Mutation, Missense , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/metabolism , Myelodysplastic Syndromes/pathology , Patient Safety , Phosphoproteins/genetics , Phosphoproteins/metabolism , Piperazines/adverse effects , Pyridines/adverse effects , RNA Splicing Factors/genetics , RNA Splicing Factors/metabolism , Treatment OutcomeABSTRACT
BACKGROUND: The current biomarkers alpha-fetoprotein and human chorionic gonadotropin have limited sensitivity and specificity for diagnosing malignant germ-cell tumours (GCTs). MicroRNAs (miRNAs) from the miR-371-373 and miR-302/367 clusters are overexpressed in all malignant GCTs, and some of these miRNAs show elevated serum levels at diagnosis. Here, we developed a robust technical pipeline to quantify these miRNAs in the serum and cerebrospinal fluid (CSF). The pipeline was used in samples from a cohort of exclusively paediatric patients with gonadal and extragonadal malignant GCTs, compared with appropriate tumour and non-tumour control groups. METHODS: We developed a method for miRNA quantification that enabled sample adequacy assessment and reliable data normalisation. We performed qRT-PCR profiling for miR-371-373 and miR-302/367 cluster miRNAs in a total of 45 serum and CSF samples, obtained from 25 paediatric patients. RESULTS: The exogenous non-human spike-in cel-miR-39-3p and the endogenous housekeeper miR-30b-5p were optimal for obtaining robust serum and CSF qRT-PCR quantification. A four-serum miRNA panel (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p): (i) showed high sensitivity/specificity for diagnosing paediatric extracranial malignant GCT; (ii) allowed early detection of relapse of a testicular mixed malignant GCT; and (iii) distinguished intracranial malignant GCT from intracranial non-GCT tumours at diagnosis, using CSF and serum samples. CONCLUSIONS: The pipeline we have developed is robust, scalable and transferable. It potentially promises to improve clinical management of paediatric (and adult) malignant GCTs.
Subject(s)
Biomarkers, Tumor/blood , Central Nervous System Neoplasms/diagnosis , MicroRNAs/blood , Neoplasm Recurrence, Local/diagnosis , Neoplasms, Germ Cell and Embryonal/diagnosis , Ovarian Neoplasms/diagnosis , Testicular Neoplasms/diagnosis , Adolescent , Biomarkers, Tumor/cerebrospinal fluid , Carcinoma, Embryonal/blood , Carcinoma, Embryonal/cerebrospinal fluid , Carcinoma, Embryonal/diagnosis , Central Nervous System Neoplasms/blood , Central Nervous System Neoplasms/cerebrospinal fluid , Child , Child, Preschool , Choriocarcinoma, Non-gestational/blood , Choriocarcinoma, Non-gestational/cerebrospinal fluid , Choriocarcinoma, Non-gestational/diagnosis , Chorionic Gonadotropin/blood , Chorionic Gonadotropin/cerebrospinal fluid , Endodermal Sinus Tumor/blood , Endodermal Sinus Tumor/cerebrospinal fluid , Endodermal Sinus Tumor/diagnosis , Female , Germinoma/blood , Germinoma/cerebrospinal fluid , Germinoma/diagnosis , Humans , Infant , Infant, Newborn , Male , MicroRNAs/cerebrospinal fluid , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/cerebrospinal fluid , Neoplasms, Germ Cell and Embryonal/blood , Neoplasms, Germ Cell and Embryonal/cerebrospinal fluid , Ovarian Neoplasms/blood , Ovarian Neoplasms/cerebrospinal fluid , Polymerase Chain Reaction , Sacrococcygeal Region , Sensitivity and Specificity , Testicular Neoplasms/blood , Testicular Neoplasms/cerebrospinal fluid , alpha-Fetoproteins/cerebrospinal fluid , alpha-Fetoproteins/metabolismABSTRACT
Meta-analysis has shown a modest improvement in first-year growth response to recombinant human GH (r-hGH) for carriers of the exon 3-deleted GH receptor (GHRd3) polymorphism but with significant interstudy variability. The associations between GHRd3 and growth response to r-hGH over 3 years in relation to severity of GH deficiency (GHD) were investigated in patients from 14 countries. Treatment-naïve pre-pubertal children with GHD were enrolled from the PREDICT studies (NCT00256126 and NCT00699855), categorized by peak GH level (peak GH) during provocation test: ≤4âµg/l (severe GHD; n=45) and >4 to <10âµg/l mild GHD; n=49) and genotyped for the GHRd3 polymorphism (full length (fl/fl, fl/d3, d3/d3). Gene expression (GE) profiles were characterized at baseline. Changes in growth (height (cm) and SDS) over 3 years were measured. There was a dichotomous influence of GHRd3 polymorphism on response to r-hGH, dependent on peak GH level. GH peak level (higher vs lower) and GHRd3 (fl/fl vs d3 carriers) combined status was associated with height change over 3 years (P<0.05). GHRd3 carriers with lower peak GH had lower growth than subjects with fl/fl (median difference after 3 years -3.3âcm; -0.3 SDS). Conversely, GHRd3 carriers with higher peak GH had better growth (+2.7âcm; +0.2 SDS). Similar patterns were observed for GH-dependent biomarkers. GE profiles were significantly different between the groups, indicating that the interaction between GH status and GHRd3 carriage can be identified at a transcriptomic level. This study demonstrates that responses to r-hGH depend on the interaction between GHD severity and GHRd3 carriage.
Subject(s)
Dwarfism, Pituitary/drug therapy , Human Growth Hormone/therapeutic use , Receptors, Somatotropin/genetics , Blood Glucose/metabolism , Body Height , Child , Cholesterol, HDL/metabolism , Cholesterol, LDL/metabolism , Dwarfism, Pituitary/genetics , Dwarfism, Pituitary/metabolism , Exons , Female , Gene Expression Profiling , Growth Disorders/drug therapy , Growth Disorders/genetics , Growth Disorders/metabolism , Human Growth Hormone/deficiency , Humans , Insulin/metabolism , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/metabolism , Longitudinal Studies , Male , Polymorphism, Genetic , Prospective Studies , Recombinant Proteins , Severity of Illness Index , Thyrotropin/metabolism , Thyroxine/metabolism , Treatment Outcome , Triglycerides/metabolismABSTRACT
BACKGROUND: A co-ordinated tissue-independent gene expression profile associated with growth is present in rodent models and this is hypothesised to extend to all mammals. Growth in humans has similarities to other mammals but the return to active long bone growth in the pubertal growth spurt is a distinctly human growth event. The aim of this study was to describe gene expression and biological pathways associated with stages of growth in children and to assess tissue-independent expression patterns in relation to human growth. RESULTS: We conducted gene expression analysis on a library of datasets from normal children with age annotation, collated from the NCBI Gene Expression Omnibus (GEO) and EBI Arrayexpress databases. A primary data set was generated using cells of lymphoid origin from normal children; the expression of 688 genes (ANOVA false discovery rate modified p-value, q < 0.1) was associated with age, and subsets of these genes formed clusters that correlated with the phases of growth--infancy, childhood, puberty and final height. Network analysis on these clusters identified evolutionarily conserved growth pathways (NOTCH, VEGF, TGFB, WNT and glucocorticoid receptor--Hyper-geometric test, q < 0.05). The greatest degree of network 'connectivity' and hence functional significance was present in infancy (Wilcoxon test, p < 0.05), which then decreased through to adulthood. These observations were confirmed in a separate validation data set from lymphoid tissue. Similar biological pathways were observed to be associated with development-related gene expression in other tissues (conjunctival epithelia, temporal lobe brain tissue and bone marrow) suggesting the existence of a tissue-independent genetic program for human growth and maturation. CONCLUSIONS: Similar evolutionarily conserved pathways have been associated with gene expression and child growth in multiple tissues. These expression profiles associate with the developmental phases of growth including the return to active long bone growth in puberty, a distinctly human event. These observations also have direct medical relevance to pathological changes that induce disease in children. Taking into account development-dependent gene expression profiles for normal children will be key to the appropriate selection of genes and pathways as potential biomarkers of disease or as drug targets.
Subject(s)
Biological Evolution , Gene Expression Profiling , Gene Expression Regulation , Gene Regulatory Networks , Growth/genetics , Adolescent , Adult , Age Factors , Animals , Carrier Proteins/genetics , Carrier Proteins/metabolism , Child , Child, Preschool , Cluster Analysis , Genome-Wide Association Study , Host Specificity/genetics , Humans , Infant , Protein Binding , Protein Interaction Mapping , Receptors, Glucocorticoid/metabolism , Signal Transduction , Young AdultABSTRACT
Our molecular understanding of growth hormone-induced signal transduction has improved significantly over the past decades. At the same time, human population genetics and the analysis of genetically engineered animals have led to the discovery of genes that control specific aspects of the overall growth process. Although, currently, growth disorders are still diagnosed and treated on empirical bases, it might soon be possible to stratify patients predominantly by genetic defect, with treatment based on our molecular understanding of the role of the affected gene in the disease.